Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2025 | Preliminary human data and clinical implications of asciminib administration during pregnancy in CML

Elisabetta Abruzzese • 5 Dec 2025
ASH 2025
Chronic Myeloid Leukemia Leukemia Asciminib

Elisabetta Abruzzese, MD, PhD, S. Eugenio University Hospital, Rome, Italy, discusses preliminary human data and clinical implications of asciminib administration during pregnancy in chronic myeloid leukemia (CML). Dr Abruzzese notes that while the outcomes are encouraging, caution is still necessary and contraception is recommended. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Elisabetta Abruzzese

Treatment-free remission in Ph+ ALL without alloSCT: ongoing research 1:48
Treatment-free remission in Ph+ ALL without alloSCT: ongoing research
Elisabetta Abruzzese • 4 Sep 2025
Exploring TKI de-escalation strategies in CML: outcomes of downgrading therapy 1:33
Exploring TKI de-escalation strategies in CML: outcomes of downgrading therapy
Elisabetta Abruzzese • 4 Sep 2025
A CML Campus study assessing the transition from high-potency to low-potency inhibitors in CML 3:51
A CML Campus study assessing the transition from high-potency to low-potency inhibitors in CML
Elisabetta Abruzzese • 6 Dec 2024
The impact of ponatinib on conception and pregnancy outcomes in patients with CML 2:13
The impact of ponatinib on conception and pregnancy outcomes in patients with CML
Elisabetta Abruzzese • 6 Dec 2024

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
MRD-guided treatment with sonrotoclax plus obinutuzumab in treatment-naive CLL: BGB-11417-101 1:45
MRD-guided treatment with sonrotoclax plus obinutuzumab in treatment-naive CLL: BGB-11417-101
Marc Hoffman • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals